Global Information
회사소개 | 문의 | 위시리스트

휴미라(아달리무맙) 바이오시밀러 임상시험 분석

Humira Biosimilars Clinical Trial Insight

리서치사 PNS Pharma
발행일 2016년 10월 상품 코드 374504
페이지 정보 영문 80 Pages
가격
US $ 1,500 ₩ 1,803,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스로 편집 및 인쇄가 불가능합니다.
US $ 1,800 ₩ 2,163,000 CD-ROM help
CD-ROM 의 형태로 우편 배송되며 편집 및 인쇄가 불가능합니다.
US $ 1,800 ₩ 2,163,000 Hard Copy help
Hard Copy의 형태로 우편 배송됩니다.
US $ 3,000 ₩ 3,606,000 PDF by E-mail (Multi-User License) help
동일 기업 내의 모든 직원들이 이용할 수 있는 라이선스입니다. 편집은 불가능하며 인쇄는 1회에 한해 가능합니다.

주의 : 본 보고서는 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



휴미라(아달리무맙) 바이오시밀러 임상시험 분석 Humira Biosimilars Clinical Trial Insight
발행일 : 2016년 10월 페이지 정보 : 영문 80 Pages

임상 파이프라인에서의 33개 휴미라(Humira) 바이오시밀러에 대해 분석했으며, 임상적 고찰, 개발 타임라인, 특허 분석, 개발 단계 등의 정보를 전해드립니다.

제1장 휴미라(아달리무맙) 임상적 고찰

  • 임상 개요
  • 기업 파트너십 및 계약
  • 특허 분석 : 적응증별
  • 희귀의약품 : 적응증 및 국가별
  • 상표 : 국가별/지역별

휴미라 바이오시밀러 임상적 고찰 : 기업별

제2장 아달리무맙(Adalimumab) 바이오시밀러 : AET BioTech/BioXpress Therapeutics

  • 임상적 고찰
  • 개발 타임라인
  • 개발 단계

제3장 아달리무맙 바이오시밀러 : Alphamab

제4장 아달리무맙 바이오시밀러 : Alteogen/Cristalia

제5장 아달리무맙 바이오시밀러 : Amgen

제6장 아달리무맙 바이오시밀러 : Axxo

제7장 아달리무맙 바이오시밀러 : Biocad

제8장 아달리무맙 바이오시밀러 : BIOCND/Genor Biopharma

제9장 아달리무맙 바이오시밀러 : Biocon/Mylan

제10장 아달리무맙 바이오시밀러 : Bionovis/The Instituto Vital Brazil

제11장 아달리무맙 바이오시밀러 : Boehringer Ingelheim

제12장 아달리무맙 바이오시밀러 : Celltrion

제13장 아달리무맙 바이오시밀러 : CinnaGen

제14장 아달리무맙 바이오시밀러 : Coherus BioSciences

제15장 아달리무맙 바이오시밀러 : Dong A ST/Meiji Seika Pharma

제16장 아달리무맙 바이오시밀러 : EMD Serono/Merck

제17장 아달리무맙 바이오시밀러 : Fujifilm Kyowa Kirin Biologics

제18장 아달리무맙 바이오시밀러 : TGene Techno Science

제19장 아달리무맙 바이오시밀러 : Harvest Moon Pharmaceuticals

제20장 아달리무맙 바이오시밀러 : Hetero Drugs

제21장 아달리무맙 바이오시밀러 : Innovent Biologics

제22장 아달리무맙 바이오시밀러 : LG Life Sciences

제23장 아달리무맙 바이오시밀러 : mAbxience

제24장 아달리무맙 바이오시밀러 : Meridian Biopharmaceuticals

제25장 아달리무맙 바이오시밀러 : Momenta Pharmaceuticals

제26장 아달리무맙 바이오시밀러 : ncobiologics

제27장 아달리무맙 바이오시밀러 : Pfizer

제28장 아달리무맙 바이오시밀러 : PlantPraxis

제29장 아달리무맙 바이오시밀러 : Reliance Life Sciences

제30장 아달리무맙 바이오시밀러 : Samsung Bioepis

제31장 아달리무맙 바이오시밀러 : Sandoz

제32장 아달리무맙 바이오시밀러 : Shanghai Henlius Biotech

제33장 아달리무맙 바이오시밀러 : Therapeutic Proteins International

제34장 아달리무맙 바이오시밀러 : Zydus Cadila

제35장 휴미라(아달리무맙) 바이오시밀러 개발 관련 특허 소송 문제

  • Amgen v/s AbbVie
  • Coherus v/s AbbVie

도표

LSH 16.10.31

"Humira Biosimilars Clinical Trial Insight" report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.

The Humira stands for Human Monoclonal Antibody in Rheumatoid Arthritis. It is also termed as Adalimumab or D2E7 and is a recombinant Immunoglobulin G1 monoclonal antibody which is specific for tumor necrosis factor alpha (TNF-α). It is a drug designed by the mode of recombinant DNA technology for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In the rheumatoid arthritis adalimumab has the equivalent efficacy as that of methotrexate.

The chemical and biological components of Humira define it as a TNF inhibiting anti-inflammatory biologic medication. It binds to the TNF-α which leads to the inflammatory response of autoimmune diseases but after the conjugation of Humira it reduces the inflammatory response.

The mechanism of action includes the binding of HUMIRA specifically to TNF-α and renders it, incapable of binding to its receptors on cell surfaces. TNF-α exerts its pro-inflammatory role by binding to its cell surface receptor. When HUMIRA binds to the membrane bound version of TNF-α on TNF-α-producing cells, it can lead to lysis of these TNF-α producing cell in the presence of complement.

TNF- α level is found elevated in the synovial fluids of rheumatoid arthritis. TNF-α is one of the important factors that contribute to the pathology and perpetuation of the inflamed and destroyed joints in rheumatoid arthritis. Given that rheumatoid arthritis is a complex disease with multiple factors involved, the ability for a monoclonal antibody to neutralize the function of one single cytokine TNF-α and greatly improve the symptoms and progression of rheumatoid arthritis.

It is produced by Abbot Laboratories but originally Humira was emerged from collaboration between Bioresearch Center in Massachusetts (BASF) and the Cambridge Antibody Technologies in the UK. Mid stage clinical trials were so promising that, at the end of 2000, Abbott agreed to buy the BASF Bioresearch Center for US$ 6.9 Billion. When Humira was launched in 2003, it was the third TNF-alpha antibody to the market. Its US, FDA approval for marketing was achieved on December 31, 2002. In 2012 to 2015 Humira topped the top selling pharmaceutical product lists and in 2015, Humira had topped US$ 14 Billion of sales globally.

However, its superior dosing schedule and improved toleration over existing therapy enabled it to become the best in class agent. Furthermore, Abbott had a robust development program for Humira and expanded its use to other inflammatory disease such as psoriasis, Crohn's disease, and juvenile idiopathic arthritis. While prescribed to far fewer patients than Lipitor, the high cost of this biological medicine is such that Humira's sales were projected to exceed US$ 9 Billion.

In December 2014, Indian drug maker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its U.S. price. The generic has been launched under the brand name Exemptia. In January 2016, another Indian drug maker Torrent Pharmaceuticals launched its biosimilar for adalimumab. Torrent's Adfrar would be the second generic biosimilar of adalimumab in the world. In September 2016 the US FDA approved Amgens biosimilar adalimumab-atto sold under the brand name Amjevita.

Table of Contents

1. Humira (Adalimumab) Clinical Insight

  • 1.1 Clinical Introduction
  • 1.2 Company Partnerships & Agreements
  • 1.3 Patent Analysis by Indication
  • 1.4 Designated Orphan Status by Indication & Country
  • 1.5 Brand Names by Country/Region

Humira Biosimilars Clinical Insight by Company

2. Adalimumab Biosimilar - AET BioTech/BioXpress Therapeutics

  • 2.1 Clinical Insight
  • 2.2 Development Timeline
  • 2.3 Phase of Development

3. Adalimumab Biosimilar - Alphamab

  • 3.1 Clinical Insight
  • 3.2 Development Timeline
  • 3.3 Phase of Development

4. Adalimumab Biosimilar - Alteogen/Cristalia

  • 4.1 Clinical Insight
  • 4.2 Phase of Development

5. Adalimumab Biosimilar - Amgen

  • 5.1 Clinical Insight
  • 5.2 Development Timeline
  • 5.3 Phase of Development

6. Adalimumab Biosimilar - Axxo

  • 6.1 Clinical Insight
  • 6.2 Phase of Development

7. Adalimumab Biosimilar - Biocad

  • 7.1 Clinical Insight
  • 7.2 Development Timeline
  • 7.3 Phase of Development

8. Adalimumab Biosimilar - BIOCND/Genor Biopharma

  • 8.1 Clinical Insight
  • 8.2 Development Timeline
  • 8.3 Phase of Development

9. Adalimumab Biosimilar - Biocon/Mylan

  • 9.1 Clinical Insight
  • 9.2 Development Timeline
  • 9.3 Phase of Development

10. Adalimumab Biosimilar - Bionovis/The Instituto Vital Brazil

  • 10.1 Clinical Insight
  • 10.2 Development Timeline
  • 10.3 Phase of Development

11. Adalimumab Biosimilar - Boehringer Ingelheim

  • 11.1 Clinical Insight
  • 11.2 Development Timeline
  • 11.3 Phase of Development

12. Adalimumab Biosimilar - Celltrion

  • 12.1 Clinical Insight
  • 12.2 Phase of Development

13. Adalimumab Biosimilar - CinnaGen

  • 13.1 Clinical Insight
  • 13.2 Phase of Development

14. Adalimumab Biosimilar - Coherus BioSciences

  • 14.1 Clinical Insight
  • 14.2 Development Timeline
  • 14.3 Phase of Development

15. Adalimumab Biosimilar - Dong A ST/Meiji Seika Pharma

  • 15.1 Clinical Insight
  • 15.2 Development Timeline
  • 15.3 Phase of Development

16. Adalimumab Biosimilar - EMD Serono/Merck

  • 16.1 Clinical Insight
  • 16.2 Development Timeline
  • 16.3 Phase of Development

17. Adalimumab Biosimilar - Fujifilm Kyowa Kirin Biologics

  • 17.1 Clinical Insight
  • 17.2 Development Timeline
  • 17.3 Phase of Development

18. Adalimumab Biosimilar - Gene Techno Science

  • 18.1 Clinical Insight
  • 18.2 Phase of Development

19. Adalimumab Biosimilar - Harvest Moon Pharmaceuticals

  • 19.1 Clinical Insight
  • 19.2 Development Timeline
  • 19.3 Phase of Development

20. Adalimumab Biosimilar - Hetero Drugs

  • 20.1 Clinical Insight
  • 20.2 Development Timeline
  • 20.3 Phase of Development

21. Adalimumab Biosimilar - Innovent Biologics

  • 21.1 Clinical Insight
  • 21.2 Development Timeline
  • 21.3 Phase of Development

22. Adalimumab Biosimilar - LG Life Sciences

  • 22.1 Clinical Insight
  • 22.2 Development Timeline
  • 22.3 Phase of Development

23. Adalimumab Biosimilar - mAbxience

  • 23.1 Clinical Insight
  • 23.2 Development Timeline
  • 23.3 Phase of Development

24. Adalimumab Biosimilar - Meridian Biopharmaceuticals

  • 24.1 Clinical Insight
  • 24.2 Phase of Development

25. Adalimumab Biosimilar - Momenta Pharmaceuticals

  • 25.1 Clinical Insight
  • 25.2 Development Timeline
  • 25.3 Phase of Development

26. Adalimumab Biosimilar - Oncobiologics

  • 26.1 Clinical Insight
  • 26.2 Development Timeline
  • 26.3 Phase of Development

27. Adalimumab Biosimilar - Pfizer

  • 27.1 Clinical Insight
  • 27.2 Development Timeline
  • 27.3 Phase of Development

28. Adalimumab Biosimilar - PlantPraxis

  • 28.1 Clinical Insight
  • 28.2 Development Timeline
  • 28.3 Phase of Development

29. Adalimumab Biosimilar - Reliance Life Sciences

  • 29.1 Clinical Insight
  • 29.2 Development Timeline
  • 29.3 Phase of Development

30. Adalimumab Biosimilar - Samsung Bioepis

  • 30.1 Clinical Insight
  • 30.2 Development Timeline
  • 30.3 Phase of Development

31. Adalimumab Biosimilar - Sandoz

  • 31.1 Clinical Insight
  • 31.2 Development Timeline
  • 31.3 Phase of Development

32. Adalimumab Biosimilar - Shanghai Henlius Biotech

  • 32.1 Clinical Insight
  • 32.2 Development Timeline
  • 32.3 Phase of Development

33. Adalimumab Biosimilar - Therapeutic Proteins International

  • 33.1 Clinical Insight
  • 33.2 Phase of Development

34. Adalimumab Biosimilar - Zydus Cadila

  • 34.1 Clinical Insight
  • 34.2 Development Timeline
  • 34.3 Phase of Development

35. Patent Litigation Issues Involving Development of Humira (Adalimumab) Biosimilar

  • 35.1 Amgen v/s AbbVie
  • 35.2 Coherus v/s AbbVie

List of Tables

  • Table 1-1: Humira Clinical Trial by Phase of Development
  • Table 1-2: Humira - Designated Orphan Status by Indication & Country
  • Table 1-3: Humira - Brand Names by Country/Region
  • Table 2-1: AET BioTech/BioXpress Therapeutics Adalimumab Biosimilar by Indication & Phase
  • Table 3-1: Alphamab Adalimumab Biosimilar by Indication & Phase
  • Table 4-1: Alteogen/Cristalia Adalimumab Biosimilar by Indication & Phase
  • Table 5-1: Amgen Adalimumab Biosimilar by Indication & Phase
  • Table 6-1: Axxo Adalimumab Biosimilar by Indication & Phase
  • Table 7-1 Biocad Adalimumab Biosimilar by Indication & Phase
  • Table 8-1: BIOCND/Genor Biopharma Adalimumab Biosimilar by Indication & Phase
  • Table 9-1: Biocon/Mylan Adalimumab Biosimilar by Indication & Phase
  • Table 10-1: Bionovis/The Instituto Vital Brazil Adalimumab Biosimilar by Indication & Phase
  • Table 11-1: Boehringer Ingelheim Adalimumab Biosimilar by Indication & Phase
  • Table 12-1: Celltrion Adalimumab Biosimilar by Indication & Phase
  • Table 13-1: CinnaGen Adalimumab Biosimilar by Indication & Phase
  • Table 14-1: Coherus BioSciences Adalimumab Biosimilar by Indication & Phase
  • Table 15-1: Dong A ST/Meiji Seika Pharma Adalimumab Biosimilar by Indication & Phase
  • Table 16-1: EMD Serono/Merck Adalimumab Biosimilar by Indication & Phase
  • Table 17-1: Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar by Indication & Phase
  • Table 18-1: Gene Techno Science Adalimumab Biosimilar by Indication & Phase
  • Table 19-1: Harvest Moon Pharmaceuticals Adalimumab Biosimilar by Indication & Phase
  • Table 20-1: Hetero Drugs Adalimumab Biosimilar by Indication & Phase
  • Table 21-1: Innovent Biologics Adalimumab Biosimilar by Indication & Phase
  • Table 22-1: LG Life Sciences Adalimumab Biosimilar by Indication & Phase
  • Table 23-1: mAbxience Adalimumab Biosimilar by Indication & Phase
  • Table 24-1: Meridian Biopharmaceuticals Adalimumab Biosimilar by Indication & Phase
  • Table 25-1: Momenta Pharmaceuticals Adalimumab Biosimilar by Indication & Phase
  • Table 26-1: Oncobiologics Adalimumab Biosimilar by Indication & Phase
  • Table 27-1: Pfizer Adalimumab Biosimilar by Indication & Phase
  • Table 28-1: PlantPraxis Adalimumab Biosimilar by Indication & Phase
  • Table 29-1: Reliance Life Sciences Adalimumab Biosimilar by Indication & Phase
  • Table 30-1: Samsung Bioepis Adalimumab Biosimilar by Indication & Phase
  • Table 31-1: Sandoz Adalimumab Biosimilar by Indication & Phase
  • Table 32-1: Shanghai Henlius Biotech Adalimumab Biosimilar by Indication & Phase
  • Table 33-1: Therapeutic Proteins International Adalimumab Biosimilar by Indication & Phase
  • Table 34-1: Zydus Cadila Adalimumab Biosimilar by Indication & Phase
Back to Top
전화 문의
F A Q